AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Sintx Technologies, Inc.

$1.71 -$2.07 (-54.79%)
NASDAQ · 14 Sep 2026 13:42 UTC
Previous Close
$1.8
Day Range
$1.71$1.78
Year Range
$1.4$5.14
Market Cap
10.87M
AVG Volume
90.81K
Trailing/Forward PE
-0.31/-
PEG ratio
0.01
Dividend Yield
-
Next Earnings Date
2026-11-11
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
0500K1M1.5M2M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SINT Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q21.38M
26 Q11.03M
25 Q41.02M
25 Q31.22M
25 Q21.38M
25 Q11.66M
24 Q41.6M
24 Q31.96M
24 Q21.76M
24 Q11.89M
Net Income (USD) · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SINT Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-18M
26 Q1-17.61M
25 Q4-17.08M
25 Q3-16.56M
25 Q2-12.54M
25 Q1-12.43M
24 Q4-11.02M
24 Q3-11.65M
24 Q2-8.6M
24 Q1-8.85M
Operating Income (USD) · TTM
-20M-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SINT Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-11.77M
26 Q1-11.54M
25 Q4-10.72M
25 Q3-10.13M
25 Q2-13.19M
25 Q1-13.23M
24 Q4-14.05M
24 Q3-15.04M
24 Q2-12.24M
24 Q1-13M
EBITDA (USD) · TTM
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SINT EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-10.71M
26 Q1-10.22M
25 Q4-9.66M
25 Q3-9.07M
25 Q2-11.59M
25 Q1-11.24M
24 Q4-9.61M
24 Q3-10.43M
24 Q2-7.26M
24 Q1-8.46M
Cash Flows (USD) · TTM
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SINT Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-10.34M
26 Q1-9.89M
25 Q4-8.76M
25 Q3-7.64M
25 Q2-7.62M
25 Q1-7.79M
24 Q4-9.33M
24 Q3-11.26M
24 Q2-11.72M
24 Q1-12.45M
EPS (USD) · TTM
-30-20-10024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SINT EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-5.41
26 Q1-5.57
25 Q4-6.16
25 Q3-6.92
25 Q2-10.41
25 Q1-12.66
24 Q4-13.27
24 Q3-18.05
24 Q2-19.41
24 Q1-22.64
Expenses (USD) · TTM
05M10M15MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SINT Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q212.58M
26 Q112M
25 Q411.21M
25 Q310.58M
25 Q28.77M
25 Q19.46M
24 Q410.5M
24 Q311.69M
24 Q213.89M
24 Q114.25M
Shares Outstanding (USD) · TTM
-3M-2M-1M01MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
SINT Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-2.39M
26 Q1-2.3M
25 Q4-1.86M
25 Q3-1.22M
25 Q2-341K
25 Q1-123K
24 Q4-82K
24 Q3-75K
24 Q2-132K
24 Q1-188K
Employee Count
02040602016201720182019202020212022202320242025
SINT Employee Count by quarter
PeriodEmployee Count
202532
202420
202343
202241
202136
202032
201928
201819
201733
201635
Free Cash Flow Yield
-800%-600%-400%-200%0%med -133.16%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
SINT Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-118.42%
Sep 26-130.77%
Aug 26-142.1%
Aug 26-137.52%
Aug 26-129.97%
Aug 26-148.49%
Jul 26-144.99%
Jul 26-176.06%
Jul 26-155.02%
Jul 26-143.31%
Jul 26-129.73%
Jun 26-128.38%
Jun 26-116.82%
Jun 26-116.27%
Jun 26-121.42%
May 26-110.04%
May 26-103.13%
May 26-108.58%
May 26-134.4%
May 26-131.06%
Apr 26-127.87%
Apr 26-117.41%
Apr 26-117.85%
Apr 26-125.34%
Mar 26-138.53%
Mar 26-126.85%
Mar 26-89.56%
Mar 26-94.83%
Feb 26-89.25%
Feb 26-85.13%
Feb 26-84.85%
Feb 26-87.73%
Jan 26-80.35%
Jan 26-73.49%
Jan 26-68.97%
Jan 26-68.24%
Jan 26-68.24%
Dec 25-68.97%
Dec 25-71.45%
Dec 25-69.9%
Dec 25-64%
Nov 25-62.15%
Nov 25-80.35%
Nov 25-81.88%
Nov 25-91.97%
Oct 25-94.27%
Oct 25-80.2%
Oct 25-75.94%
Oct 25-72.64%
Oct 25-76.33%
Sep 25-66.24%
Sep 25-61%
Sep 25-69.13%
Sep 25-54.58%
Aug 25-72.47%
Aug 25-86.17%
Aug 25-98.93%
Aug 25-152.03%
Aug 25-183.07%
Jul 25-156.92%
Jul 25-158.62%
Jul 25-131.95%
Jul 25-131.16%
Jun 25-136.45%
Jun 25-139.49%
Jun 25-134.37%
Jun 25-154.71%
May 25-162.13%
May 25-163.34%
May 25-139.04%
May 25-268.32%
May 25-250.88%
Apr 25-269.36%
Apr 25-397.11%
Apr 25-365.76%
Apr 25-337.35%
Mar 25-250.88%
Mar 25-231.65%
Mar 25-367.46%
Mar 25-379.67%
Feb 25-379.67%
Feb 25-236.67%
Feb 25-426.01%
Feb 25-387.88%
Jan 25-413.39%
Jan 25-391.5%
Jan 25-395.19%
Jan 25-370.71%
Jan 25-340.57%
Dec 24-332.46%
Dec 24-357.02%
Dec 24-405.39%
Dec 24-336.92%
Nov 24-313.4%
Nov 24-253.37%
Nov 24-616.04%
Nov 24-642.53%
Nov 24-595.16%
Oct 24-578.47%
Oct 24-571.36%
Price to Sales
02.557.51012.5med 5.94Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
SINT Price to Sales by quarter
PeriodPrice to Sales
Sep 266.32
Sep 265.72
Aug 265.27
Aug 265.44
Aug 265.76
Aug 266.48
Jul 266.63
Jul 265.46
Jul 266.2
Jul 266.71
Jul 267.41
Jun 267.49
Jun 268.23
Jun 268.27
Jun 267.92
May 268.74
May 269.32
May 268.86
May 266.4
May 266.57
Apr 266.73
Apr 267.33
Apr 267.3
Apr 266.87
Mar 266.21
Mar 266.78
Mar 267
Mar 266.61
Feb 267.03
Feb 267.37
Feb 267.39
Feb 267.15
Jan 267.8
Jan 268.53
Jan 269.09
Jan 269.19
Jan 269.19
Dec 259.09
Dec 258.78
Dec 258.97
Dec 259.8
Nov 2510.09
Nov 257.8
Nov 257.66
Nov 256.02
Oct 255.87
Oct 256.9
Oct 257.29
Oct 257.62
Oct 257.25
Sep 258.35
Sep 259.07
Sep 258
Sep 2510.14
Aug 257.63
Aug 256.42
Aug 255.59
Aug 253.09
Aug 252.57
Jul 253
Jul 252.97
Jul 253.56
Jul 253.59
Jun 253.45
Jun 253.37
Jun 253.5
Jun 253.04
May 252.9
May 252.88
May 253.38
May 252.18
May 252.33
Apr 252.17
Apr 251.47
Apr 251.6
Apr 251.73
Mar 252.33
Mar 252.52
Mar 251.57
Mar 251.52
Feb 251.52
Feb 252.43
Feb 251.35
Feb 251.48
Jan 251.39
Jan 251.47
Jan 251.46
Jan 251.55
Jan 251.69
Dec 241.73
Dec 241.61
Dec 241.42
Dec 241.71
Nov 241.84
Nov 242.27
Nov 240.93
Nov 241.04
Nov 241.12
Oct 241.15
Oct 241.17
Price to Book
051015med 2Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
SINT Price to Book by quarter
PeriodPrice to Book
Sep 261.81
Sep 261.64
Aug 261.51
Aug 261.56
Aug 261.65
Aug 267.37
Jul 267.55
Jul 266.22
Jul 267.06
Jul 267.64
Jul 268.44
Jun 268.53
Jun 269.37
Jun 269.41
Jun 269.01
May 269.95
May 2610.61
May 2610.08
May 262.23
May 262.28
Apr 262.34
Apr 262.55
Apr 262.54
Apr 262.39
Mar 262.16
Mar 262.36
Mar 262.1
Mar 261.98
Feb 262.11
Feb 262.21
Feb 262.21
Feb 262.14
Jan 262.34
Jan 262.56
Jan 262.72
Jan 262.75
Jan 262.75
Dec 252.72
Dec 252.63
Dec 252.69
Dec 252.94
Nov 253.02
Nov 252.34
Nov 252.29
Nov 252.08
Oct 252.03
Oct 252.38
Oct 252.52
Oct 252.63
Oct 252.5
Sep 252.89
Sep 253.13
Sep 252.77
Sep 253.5
Aug 252.64
Aug 252.22
Aug 251.93
Aug 250.84
Aug 250.7
Jul 250.81
Jul 250.81
Jul 250.97
Jul 250.97
Jun 250.94
Jun 250.92
Jun 250.95
Jun 250.83
May 250.79
May 250.78
May 250.92
May 250.89
May 250.96
Apr 250.89
Apr 250.6
Apr 250.66
Apr 250.71
Mar 250.96
Mar 251.03
Mar 250.55
Mar 250.53
Feb 250.53
Feb 250.85
Feb 250.47
Feb 250.52
Jan 250.49
Jan 250.52
Jan 250.51
Jan 250.54
Jan 250.59
Dec 240.61
Dec 240.57
Dec 240.5
Dec 240.6
Nov 240.64
Nov 240.8
Nov 240.33
Nov 240.21
Nov 240.22
Oct 240.23
Oct 240.23
Sintx Technologies, Inc.
SINT
Stockpicker

Video analysis: SINT

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: SINT

SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts

globenewswire.com · 14 Sep 2026

SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts

Experts in implant retrieval, biomaterials and clinical practice examine the science, clinical experience and potential advantages of silicon nitride relative to established implant materials in Company-sponsored Orthopedics This Week Masterclass SALT LAKE CITY, Utah, Sept. 14, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced the availability of a Company-sponsored Masterclass hosted by Orthopedics This Week (“OTW”), the most widely read publication in the orthopedics industry, that brings together three industry experts to present arguments examining the value of silicon nitride over legacy implant materials and to increase awareness of the impact it may have in orthopedic applications.

SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

globenewswire.com · 8 Sep 2026

SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SALT LAKE CITY, Utah, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced that it will participate in the 28th Annual H.C.

SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade

zacks.com · 19 Aug 2026

SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade

SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SINTX Technologies Regains Compliance with Nasdaq Stockholders' Equity Requirement

globenewswire.com · 13 Aug 2026

SINTX Technologies Regains Compliance with Nasdaq Stockholders' Equity Requirement

SALT LAKE CITY, Utah, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain minimum stockholders' equity of $2.5 million. Based on SINTX's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which reported stockholders' equity of approximately $4.83 million, Nasdaq determined that the Company complies with the minimum stockholders' equity requirement under Listing Rule 5550(b)(1) and confirmed that the previously disclosed deficiency matter is now closed.

Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript

seekingalpha.com · 11 Aug 2026

Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript

Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript

SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

globenewswire.com · 11 Aug 2026

SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

SALT LAKE CITY, Utah, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today provided a business update in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. During the first half of 2026, SINTX advanced the commercialization of its FDA-cleared SiNAPTIC® Foot & Ankle Implant System, expanded its commercial distribution network, raised additional capital, invested in advanced manufacturing capabilities, and continued to broaden the application of its proprietary silicon nitride technology platform across multiple healthcare and industrial markets.

SINTX Technologies Announces Second Quarter 2026 Earnings Release Date and Webcast

globenewswire.com · 28 Jul 2026

SINTX Technologies Announces Second Quarter 2026 Earnings Release Date and Webcast

SALT LAKE CITY, Utah, July 28, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride ceramics and advanced material technologies, today announced that it will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after the market close. The Company will also host a conference call and webcast that day at 4:30 p.m.

SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program

globenewswire.com · 23 Jul 2026

SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program

SALT LAKE CITY, Utah, July 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced biomaterials and silicon nitride technologies for medical device and industrial applications, today announced that it has engaged Southern Metrics Consulting (“Southern Metrics”) to assist the Company in identifying, evaluating, and pursuing strategic opportunities intended to enhance stockholder value. Southern Metrics is led by Chris Lyons, its Chief Executive Officer, an experienced medical technology executive and strategic advisor who has served on the SINTX Board of Directors since April 2025. Southern Metrics will establish and manage the Company's newly created Strategic Opportunity Management Program.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.